论文部分内容阅读
目的:进一步研究和比较临床治疗急性脑梗死实践过程中采用依达拉奉联合奥扎格雷钠治疗方法的实际治疗效果,从而为临床实践提供指导和依据。方法:以本院2010年12月-2012年12月收治的急性脑梗死患者92例为研究对象进行了回顾性分析。结果:实施治疗前,两组患者的NIHSS评分和ADL指数评分结果比较差异无统计学意义;实施治疗后14 d和30 d,联合用药组患者的NIHSS评分和ADL指数评分结果显著地低于单纯用药组患者水平,比较差异具有统计学意义(P<0.05)。结论:在临床针对急性脑梗死患者实施治疗的过程中采用依达拉奉联合奥扎格雷钠治疗方法的临床治疗效果显著,是临床治疗急性脑梗死患者的安全可靠选择。
Objective: To further study and compare the actual treatment effect of edaravone combined with ozagrel sodium in clinical treatment of acute cerebral infarction, so as to provide guidance and basis for clinical practice. Methods: A total of 92 acute cerebral infarction patients admitted from December 2010 to December 2012 in our hospital were retrospectively analyzed. Results: Before the treatment, there was no significant difference between the two groups in NIHSS score and ADL index score. After 14 and 30 days of treatment, NIHSS score and ADL index score in combination group were significantly lower than those in simple group The level of patients in the medication group was significantly different (P <0.05). Conclusion: The clinical effect of edaravone combined with ozagrel sodium in the clinical treatment of patients with acute cerebral infarction is significant. It is a safe and reliable choice for the clinical treatment of patients with acute cerebral infarction.